Polycystic ovary syndrome (PCOS), which is associated with hyperinsulinaemia,
hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the
adipose tissue, is a heterogeneous reproductive and endocrine disorder.Currently, metformin,
a classical and common insulin sensitizer that can reduce both hyperinsulinemia and
hyperandrogenemia, is widely used for patients with PCOS. SGLT-2 inhibitor, a novel
glucose-lowering medication, have been shown to have positive effects on reducing body
weight, blood pressure and cardiovascular events in individuals with diabetes mellitus.
However, evidences related to its management in non-diabetic PCOS women are limited. Hence,
we want to give canangliflozin combined with metformin to women with PCOS to see its effect
on insulin resistance.